Global stock

XETRAEUR

QIAGEN NV

QIAG.DE

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

62/ 100

Overall score·QIAG.DE

Current price

45.05EUR

23/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Hodnotu podporuje PEG 1,35 a P/B kolem 3,1, zatímco P/E 26,7 a cena nad uvedeným cílem analytiků ukazují na spíše napjaté ocenění. Ziskovost a nízká beta jsou relativně silné stránky, růst tržeb je však téměř stagnující; cenové momentum je výrazně pozitivní.

§ Outlook vs S&P 500Next 12 months

Probably yes

Estimated chance of beating the index: about 55%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Context and events

Management

Jonathan M. Pratt je CEO a člen představenstva; Roland Sackers zastává funkci CFO, výkonného ředitele a člena představenstva. Strategie společnosti stojí na dodávkách diagnostických a výzkumných technologií a na rozvoji produktů pro molekulární analýzu. Antonio Santos vede globální provoz a Daniel Wendorff odpovídá za vztahy s investory.

Articles about QIAGEN NV, in Czech (0)

No articles yet. New analyses are published daily.

§ Upcoming results

4 November 2026

in 8 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is QIAGEN NV (QIAG.DE)?

QIAGEN NV (QIAG.DE) is a global stock traded on XETRA. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the QIAGEN NV price today?

As of 23 October 2026, QIAGEN NV trades at about 45.05 EUR per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy QIAGEN NV?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does QIAGEN NV pay a dividend?

QIAGEN NV either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is QIAGEN NV a good investment in 2026?

Our AI signal currently rates QIAGEN NV as slightly positive (score 59/100). Financial health comes out at 62/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy QIAGEN NV

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Earnings in 8 days

On 4 November 2026 the company publishes its quarterly results. This period tends to bring large price moves — the signal below does not reflect the results yet.

News summary

No newer news

Signal 02/10, 16:30

Trh sleduje spíše stabilní vyhlídky z S&T sektoru; vyhlídky QIAGEN zůstávají domesticky omezené, technický obraz naznačuje vyčkávání.

Poslední globální zprávy se netýkají přímo QIAGEN; makro prostředí a obecný scénář podporují neutrální výhled. Technicky zatím chybí jasný impuls, cena by mohla zůstat v úzkol ose konsolidace, RSI kolem 50–60 ukazuje neutrální moment.

Risks: Možné zpomalení ve farmaceutickém sektoru, změny v regulatorním prostředí, případný negativní překvapení z dat o onkologiích či diagnostice.

More about the signal

Risks: Možné zpomalení ve farmaceutickém sektoru, změny v regulatorním prostředí, případný negativní překvapení z dat o onkologiích či diagnostice.

Signal history· 1

28/0909:0163 · Slightly positive
Makro prostředí i sektor reagují neutrálně; nejnovější zprávy naznačují opatrný trend v inovacích a firemních výsledcích. Technická data a cenový pohyb zatím nepřinášejí jasný guidance.

The full 90-day signal history is part of Premium.

Ask the AI

DCF valuation

A DCF model is not suitable for this asset class.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 15 of 18

Valuation score

1/ 6

4/6 tests available

1. Below DCF fair value

The complete DCF range or the current price is missing.

2. Well below DCF value

The complete DCF range or the current price is missing.

3. Price vs. the last year

100% above the 1-year low (32.00 EUR to 45.05 EUR), based on stored daily prices.

4. P/E vs. similar companies

P/E 26.7 vs. median 26.4 (71 companies).

5. P/E relative to growth

PEG 1.4; a lower value means cheaper growth.

6. Analyst price target

-10.8% vs. the current price, 5 analysts.

Price and fair value

no complete range

The DCF check appears once both the price and the model range are available.

Price vs analyst target

Current price

45.05 EUR

Low 32.00 EURHigh 46.50 EUR

Current priceAverage: 40.20 EUR

DCF gap

no complete range

The DCF check appears once both the price and the model range are available.

Analyst target

-10.8%

Average target 40.20 EUR vs. price 45.05 EUR.

Analyst consensus

Target range

32.00 EUR - 46.50 EUR

Coverage

5 analysts

Analyst consensus

2.8 / 5

Changes 180 d

+3 / -1

EPS next year

7.6%

Revenue next year

5.0%

Valuation multiples

26.7

3.1

1.4

52-week range100% above the low

32.00 EUR45.05 EUR

8.0%

0.0%

19.5%

11.9%

Price vs 50D15.9%

Price vs 200D23.3%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení má jasné zaměření na diagnostické a výzkumné technologie a governance riziko je podle dodaných údajů nízké. Omezená konkrétní data o výsledcích exekuce brání vyššímu hodnocení.

strong

QIAGEN těží ze specializovaných technologií, laboratorních přístrojů a navázaných spotřebních materiálů, které mohou podporovat opakované nákupy a zákaznickou loajalitu. Konkurenční tlak a citlivost na financování výzkumu tuto výhodu částečně oslabují.

Information

Type: Global stock
Symbol: QIAG.DE
Exchange: XETRA
Currency: EUR
Sector: Healthcare
: 26.7x
: 9.3B USD
: 49.3 %
: 0.61

§ Risk profile

Výsledky mohou kolísat podle výdajů nemocnic, výzkumných institucí a farmaceutických společností. Českému investorovi přidává měnové riziko kurz EUR/CZK; významná jsou také regulatorní a konkurenční rizika v diagnostice.

Ask the AI about QIAGEN NV All signals